Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEVorsetuzumabmafodotinCat.No.:HY-P99334CASNo.:1165741-01-4Synonyms:Anti-HumanCD70RecombinantAntibody;SGN-75作?靶點:Antibody-DrugConjugates(ADCs);Microtubule/Tubulin作?通路:Antibody-drugConjugate/ADCRelated;CellCycle/DNADamage;Cytoskeleton儲存?式:PleasestoretheproductundertherecommendedconditionsintheCertificateofAnalysis.BIOLOGICALACTIVITY?物活性Vorsetuzumabmafodotin(SGN-75)?種于Auristatin的抗CD70抗體藥物偶聯(lián)物(ADC)Vorsetuzumabmafodotin由?化單克隆抗體Vorsetuzumab和ADC細(xì)胞毒素MMAF組成，具有抗腫瘤活性。體外研究Vorsetuzumabmafodotin(SGN-75;0.01-10000ng/mL;for96?h)inducesdose-dependentcytotoxicitythatisspecificwithanIC50of29?ng/mL[1].CellCytotoxicityAssay[1]CellLine:SK-OV-3cellsConcentration:0.01ng/mL,0.1ng/mL,1ng/mL,10ng/mL,100ng/mL,1000ng/mL,10000ng/mLIncubationTime:96?hResult:Induceddose-dependentcytotoxicity.體內(nèi)研究Vorsetuzumabmafodotin(SGN-75;3?mg/kg;fourintraperitonealinjectionsat4-dayinterval)significantlyreducesmediantumourvolumesanddelaystumourgrowth[1].AnimalModel:Nude(nu/nu)femalemiceinjectedwithMiaPaCa-2/CD70tumourpieces[1]Dosage:3?mg/kgAdministration:Intraperitonealinjection;every4days;foratotaloffourdoses1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemEResult:Significantlyreducedmediantumourvolumesanddelayedtumourgrowth.REFERENCES[1].MCRyan,etal.Targetingpancreaticandovariancarcinomasusingtheauristatin-basedanti-CD70antibody-drugconjugateSGN-75.BrJCancer.2010Aug24;103(5):676-84.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Tel:400-820-3792;021-58